Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury THIS PRESS...
ONWARD® Medical reçoit la classification De Novo de la FDA et l'autorisation de mise sur le marché américain pour le premier système non invasif au monde de stimulation de la moelle épinière...
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) ARC-EX System is the first and only FDA approved technology...
EcoVadis silver medal recognizes Company's environmental and social impact Demonstrates ongoing commitment to integrating sustainable business practices EINDHOVEN, the Netherlands, Dec. 12, 2024...
ONWARD Medical Ranks in Top 15 Percent Globally for Corporate Sustainability EcoVadis silver medal recognizes Company's environmental and social impact Demonstrates ongoing commitment to...
Raised EUR 50 million in new capital with cornerstone investment from Ottobock, now the Company’s top investor Signed exclusive license with CEA to develop and commercialize WIMAGINE...
ONWARD Medical Provides Q3 2024 Update and Year-to-Date Highlights Raised EUR 50 million in new capital with cornerstone investment from Ottobock, now the Company’s top investor Signed exclusive...
ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after Stroke Grant supports the first clinical trials studying the potential for brain-computer interface...
Grant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after stroke...
ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date Highlights Company to provide update on significant milestones and near-term plans, including its recent successful...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.48 | 9.56175298805 | 5.02 | 5.6 | 4.77 | 406404 | 5.13369904 | DE |
| 4 | 0.82 | 17.5213675214 | 4.68 | 5.6 | 4.54 | 119942 | 4.96951562 | DE |
| 12 | 0.2 | 3.77358490566 | 5.3 | 6.3 | 4.51 | 109772 | 5.06758832 | DE |
| 26 | 0.65 | 13.4020618557 | 4.85 | 6.3 | 4.51 | 60235 | 5.05101085 | DE |
| 52 | 2.4 | 77.4193548387 | 3.1 | 6.58 | 1.85 | 76454 | 5.0043637 | DE |
| 156 | -3.9 | -41.4893617021 | 9.4 | 12.28 | 1.85 | 30841 | 5.11677297 | DE |
| 260 | -7.52 | -57.757296467 | 13.02 | 13.28 | 1.85 | 30443 | 5.45087711 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
